Impact of Epstein–Barr Virus Protein on Hodgkin's Disease
Author Information
Author(s): Glavina-Durdov M, Jakic-Razumovic J, Capkun V, Murray P
Primary Institution: Department of Pathology and Department of Nuclear Medicine University Hospital Split, Institute of Pathology Clinical Medical Center ‘Rebro’ Zagreb, Croatia, Department of Pathology, Division of Cancer Studies, University of Birmingham, Birmingham, B15 2TT, UK
Hypothesis
Does the expression of Epstein–Barr virus-encoded latent membrane protein-1 (LMP1) affect treatment response and survival in Hodgkin's disease?
Conclusion
LMP1 expression in Hodgkin's disease cells is associated with better prognosis, especially in younger patients and those with early-stage disease.
Supporting Evidence
- LMP1 expression was found in 26% of Hodgkin's disease cases.
- Patients with lymphocyte depletion subtype had poorer outcomes compared to other subtypes.
- Younger patients with EBV had significantly longer disease-free survival.
Takeaway
This study found that a specific protein from a virus can help predict how well patients with Hodgkin's disease will do, especially if they are younger.
Methodology
Immunohistochemistry was used to analyze LMP1 expression in paraffin tissue from patients with Hodgkin's disease.
Participant Demographics
100 adult immunocompetent patients with Hodgkin's disease.
Statistical Information
P-Value
P = 0.002
Confidence Interval
95% Cl 1.07–38.5
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website